Clinical trials: Bronchiectasis, Non-Cystic Fibrosis
Bronchiectasis, Non-cystic Fibrosis Bronchiectasis
Hypertonic Saline in NCFB
The purpose of this single arm clinical trial is to evaluate the effects of 7% hypertonic saline (HS) delivered by nebulizer on clearance of mucus from the lungs in people with bronchiectasis (dilated airways) not due to cystic…
- Trial name
- NCT06242795
- Testing
- 7% Hypertonic Saline via nebulization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Bronchiectasis Adult
A Prospective Study of Factors Related to Exacerbation and Mortality of Non-cystic Fibrosis Bronchiectasis in Hong Kong
Bronchiectasis is associated with repeated exacerbations which occurs at rates of 1.5-6.5 per patients per year, and are associated with an increased risk of admission and readmission to hospital, and high health care costs.
- Trial name
- NCT04538859
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Non-cystic Fibrosis Bronchiectasis
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE.
- Trial name
- NCT05495243
- Testing
- ARINA-1
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Renovion, Inc.
Bronchiectasis
A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis
The investigators hypothesise that long term statin treatment will improve patients' symptoms through its anti-inflammatory effect.
- Trial name
- NCT01299181
- Testing
- Atorvastatin
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Edinburgh
Non-cystic Fibrosis Bronchiectasis
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
This study is open to adults with non-cystic fibrosis bronchiectasis. The main purpose of this study is to find out how a medicine called BI 1323495 is tolerated by people with non-cystic bronchiectasis.
- Trial name
- NCT04656275
- Testing
- BI 1323495
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
BRONCHIECTASIS
Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa
Statins are a class of drug used to prevent heart attacks and strokes by lowering blood cholesterol levels. They have also been found to have a beneficial "side effect" of lowering the level of inflammation in the body.
- Trial name
- NCT01299194
- Testing
- ATORVASTATIN
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- University of Edinburgh
Bronchiectasis
Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis?
Bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. One of the main forms of treatment is chest physiotherapy.
- Trial name
- NCT00816309
- Testing
- Acapella Physiotherapy
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- NHS Lothian
COPD, Respiratory Tract Infections
Targeted AntiBiotics for Chronic Pulmonary Diseases
This is a prospective, randomized multi-center trial investigating the impact of lower airway infection with P. aeruginosa in COPD patients. The aim of the study is to evaluate if targeted antibiotic therapy against P.
- Conditions
- COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa, Bronchiectasis
- Trial name
- Target-ABC (NCT03262142)
- Testing
- Piperacillin/tazobactam, Ciprofloxacin
- Where
- Denmark
- Volunteers
- 51 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Non-cystic Fibrosis Bronchiectasis
Mortality in Non-cystic Fibrosis Bronchiectasis
In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards.
- Trial name
- NCT01792427
- Where
- Belgium
- Volunteers
- 253 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Non-cystic Fibrosis Bronchiectasis, Healthy
The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis
Non-cystic fibrosis bronchiectasis patients (and controls) were recruited for the study. The investigators' aim was to study the relevance of clinical parameters in terms of underlying disease severity, proteolysis and…
- Trial name
- NCT01792440
- Where
- Belgium
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Chronic Suppurative Lung Disease, Protracted Bacterial Bronchitis
Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases
This is a prospective, single-center, two-arm (1:1), assessor-blinded, randomized controlled clinical trial that will be conducted in collaboration with the outpatient clinic of the third Pediatric Pulmonology Unit, "Attikon"…
- Conditions
- Chronic Suppurative Lung Disease, Protracted Bacterial Bronchitis, Primary Ciliary Dyskinesia (PCD), Non Cystic Fibrosis Bronchiectasis
- Trial name
- NCT07376187
- Testing
- Videoconferencing (Vsee platform), Specially designed website (FysΑΩ)
- Where
- Greece
- Volunteers
- 32 people
- Sponsor
- University of Thessaly
Non-Cystic Fibrosis Bronchiectasis
Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"
The purpose of this study is to evaluate the safety and efficacy of Ciprofloxacin for Inhalation in the treatment of patients with non-cystic fibrosis (CF) bronchiectasis.
- Trial name
- NCT00889967
- Testing
- Ciprofloxacin for Inhalation
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Aradigm Corporation
Non-cystic Fibrosis Bronchiectasis (NCFBE)
A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.
- Trial name
- NCT05601778
- Testing
- HSK31858
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-cystic Fibrosis Bronchiectasis, Pulmonary Rehabilitation
Exercise Capacity in Non-cystic Fibrosis Bronchiectasis After a Pulmonary Rehabilitation Home-based Program
A number of studies have described low exercise capacity and physical activity in patients with non-cystic fibrosis bronchiectasis (non-CF Bronchiectasis), although little research exists on using the cardiopulmonary exercise…
- Trial name
- NCT05369624
- Testing
- Pulmonary rehabilitation home-based program intervention group (PRHP)(IG)
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Hospital Universitario Virgen Macarena
Non-cystic Fibrosis Bronchiectasis
A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.
- Trial name
- NCT06660992
- Testing
- HSK31858, tablet
- Where
- 2 sites in China
- Volunteers
- 669 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Bronchiectasis
Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis
The primary objective of this study is to assess the safety and tolerability of 28 day oral administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE).
- Trial name
- NCT01818544
- Testing
- BAY85-8501
- Where
- 33 sites in France, Germany and 3 more
- Volunteers
- 94 people
- Sponsor
- Bayer
Non-cystic Fibrosis Bronchiectasis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo on the time to the first pulmonary exacerbation in study participants with non-cystic fibrosis bronchiectasis (NCFB)
- Trial name
- ATMOS (NCT07720375)
- Testing
- Galvokimig
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- UCB Biopharma SRL
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
- Trial name
- NCT06603246
- Testing
- GDC-6988
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Genentech, Inc.
Non-cystic Fibrosis Bronchiectasis, Chronic Mucus Hypersecretion
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and…
- Trial name
- NCT06237348
- Testing
- Simeox, Control
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Physio-Assist